IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No. : PCT/DE2004/001897

International Filing Date : 26 August 2004 (26.08.2004)

Priority Date(s) Claimed : 26 August 2003 (26.08.2003)

Applicant(s) (DO/EO/US) : Uwe FIEBIG, et al.

Title: INDUCTION OF ANTIVIRAL NEUTRALIZING ANTIBODIES IN HUMANS AND ANIMALS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

Timing and Fees

\boxtimes		37 C.F.R. § 1.97(b), no fee or statement is required for filing this information sure statement is filed:				
		within three months of the filing date of a national application other than a CPA under § 1.53(d);				
	\boxtimes	within three months of the actual filing date of the national phase of a PCT application; OR				
		before the mailing of a first substantive office action (including after filing of an RCE).				
		37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods ed in 37 C.F.R. § 1.97(b), but before the mailing date of:				
		a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and				

		is acco	ompanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
	Under date of	37 C.F. f the fol	R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:
		a final	action under 37 C.F.R. § 1.113;
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);
		OR a r	notice of allowance under 37 C.F.R. § 1.311;
	AND i	is filed o	on or before payment of the issue fee; AND is accompanied by:
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 00 under 37 C.F.R. § 1.17(p).
Statem	nents Ur	nder 37	C.F.R. 1.97(e)
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.
Cited I	Materia	<u>ls</u>	
		ancest	or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).
	\boxtimes	_	s of materials listed but not attached were cited in an international search dated <u>September 15, 2005</u> .
		Not re	quired by 37 CFR § 1.98.
		Copies	s of the materials listed are attached (except for the foregoing).

Non-Englis	h Language References
\boxtimes	An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
	A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:
	 X = document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document A = document defining the general state of the art O = non-written disclosure P = intercalated document T = document cited to understand the theory or principle underlying the invention
	E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date D = cited in the application L = cited for another reason & = publication of member of same patent family
	Translation of other relevant information on foreign search report
Other Infor	mation_
Payment of	Fees Due (If Any):
A c	neck for \$ covering the fee identified above is attached.
Plea	se charge to Deposit Account No. 13-3402 \$ for the fee identified above.

10/569797 CT/PTC 27 FEB 2006

 \boxtimes The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zelano, Reg. No. 27,969 Attorney/gent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza I 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: GULDE-0068

Date: February 27, 2006

AJZ:ssr

10/569797 27 FEB 2008

Please type a plus sign (+) inside this box -> +

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known **Application Number** USNP of PCT/DE2004/001897 INFORMATION DISCLOSURE Filing Date 26 August 2004 (26.08.2004) STATEMENT BY APPLICANT Uwe FIEBIG, et al. First Named Inventor Group Art Unit unknown (use as many sheets as necessary) **Examiner Name** unknown Sheet of 2 GULDE-0068 Attorney Docket Number

	ŀ		U.S. Patent Document			
	Date of Publication of Cited Doc MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Kind Code ² (<i>if known</i>)	Number	Cite No.1	Examiner Initials *
03	06-12-2003	GROGAN, ET AL.	A1	2003/108560	001	/SS/
03	10-07-2003	HART, ET AL.	B1	6,630,144	002	ã.
92	06-23-1992	BOLLING, ET AL.	Α	5,124,255	003	*
02	10-17-2002	BAISTED, ET AL.	A1	2002/151473	004	V
04	05-20-2004	AUDIT, ET AL.	A1	2004/096972	005	755/
		,				
			1			
_						

				FOREIG	N PATENT DOCUMENTS			
			Foreign Patent Docun	nent		Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner Initials*	Cite No.1	Office ³	Number⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T ⁶
/SS/	006	wo	02/079239	1 A	U.S. ARMY MED. RESEARCH INST., ET AL.	10-10-2002		001
COCCODOCO	007	wo	01/16183		U.S. ARMY MED. RESEARCH INST., ET AL.	03-08-2001		002
200000	008	FR	2 586 427	Α	PASTEUR INST	02-27-1987		
0000	009	EP	0 331 961	Α	ABBOTT LABORATORIES	09-13-1989		003
\ /	010	wo	98/20036	Α	GENENTECH, INC.	05-14-1998		004
/SS/	011	DE	199 57 838	A1	HEINRICH-PETTE INST	06-13-2001		
/33/	012	FR	2 832 424	Α	GENETHON III	05-23-2003		005

	Examiner Signature	/Stuart Snyder/	Date Considered	05/22/2008
--	-----------------------	-----------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

!APS RGC'd PCT/PTO 27 FEB 2006 10/569797

Please type a plus sign (+) inside this box -> +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute f	or form 1449A/PTO			Complete if Known		
INICO	RMATION	nec.	OCUDE	Application Number	USNP of PCT/DE2004/001897	
				Filing Date	26 August 2004 (26.08.2004)	
STATEMENT BY APPLICANT				First Named Inventor	Uwe FIEBIG, et al.	
				Group Art Unit	unknown	
(use as many shee	ts as ne	cessary)	Examiner Name	unknown	
Sheet	2	of	2	Attorney Docket Number	GULDE-0068	

44 - 1	Section 5	NON PATENT LITERATURE DOCUMENTS	+ 1
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
/SS/	013	DATABASE EBI [ONLINE] 01 AUGUST 1990; XP002341810	
\$- 	017	FIEBIG U ET AL: "NEUTRALIZING ANTIBODIES AGAINST CONSERVED DOMAINS OF p15E OF PORCINE ENDOGENOUS RETROVIRUSES: BASIS FOR A VACCINE FOR XENOTRANSPLANTATION?" VIROLOGY, RAVEN PRESS, NEW YORK, NY, US, vol. 307, no. 2, 15 MARCH 2003, PAGES 406-413, XP002269727; ISSN: 0042-6822	
V	015	DATABASE EMBL [ONLINE], 01 MAY 2000, XP002341811	
755/	016	DATABASE EBI [ONLINE], 13 AUGUST 1987, XP002341812	
	-		
	-		
		·	

				_
Examiner	/Stuart Snyder/	Date	05/22/2008	
Signature	,	Considered	03/22/2000	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.